Oderich Gustavo S, Bower Thomas C, Cherry Kenneth J, Panneton Jean M, Sullivan Timothy M, Noel Audra A, Carmo Michele, Cha Stephen, Kalra Manju, Gloviczki Peter
Division of Vascular Surgery, Mayo Clinic, Rochester, Minnesota 55905, USA.
J Vasc Surg. 2006 Jun;43(6):1166-74. doi: 10.1016/j.jvs.2006.02.040.
The primary purpose of this study was to analyze the clinical outcome in patients treated for aortic graft infections with in situ reconstruction (ISR). As a secondary aim, the outcomes were compared between patients who had similar clinical characteristics and extent of infection, needed total graft excision, and had either ISR or axillofemoral reconstruction (AXFR).
117 consecutive patients treated for aortic graft infection over a 20 year period from January 1981 to December 2001 were identified. 52 patients had prosthetic ISR, 49 had AXFR, and 16 had other reconstructions. The ISR patients treated with total (n = 35) or partial (n = 17) graft excision comprised the primary analysis. A second analysis was done between 34 ISR and 43 AXFR patients (non-concurrent groups), as stated above. Primary outcome measures were early and late procedure-related death, primary graft patency and limb loss. Secondary outcomes were operative morbidity, patient survival, and graft reinfection rates.
There were 40 males and 12 females with a mean age of 69 years treated with ISR. 43 patients had Rifampin-soaked grafts and 39 had omental flap or other autogenous coverage. Operative morbidity occurred in 23 patients (44%). There were 4 early and no late procedure-related deaths after a median follow up of 3.4 years (range, 2 months to 9.6 years). Primary patency and limb salvage rates at 5 years were 89% and 100%, respectively. Graft reinfection occurred in 6 patients (11.5%) and was not associated with procedure-related death. In the comparative analysis, the procedure-related death rate for patients treated with ISR was not different than those treated with AXFR (9% versus 23%; P = 0.11). There was a significant improvement in primary patency between ISR and AXFR at 5 years (89% versus 48%; P = .01). Limb salvage was 100% for ISR and 89% for AXFR at 5 years (P = .06). The incidence of graft reinfection was similar in both groups: 11% for ISR and 17% for AXFR (P = .28). Major complications or procedure-related deaths occurred in 12 patients after ISR (30%) and 26 patients (60%) after AXFR (P < .04).
ISR is a safe and effective alternative in the treatment of select patients with aortic graft infection. Graft reinfection occurred in 11.5% of the patients. The graft patency and limb salvages rates are excellent.
本研究的主要目的是分析采用原位重建(ISR)治疗主动脉移植物感染患者的临床结局。作为次要目的,对临床特征和感染范围相似、需要完全切除移植物、接受ISR或腋股动脉重建(AXFR)的患者的结局进行比较。
确定了1981年1月至2001年12月这20年间连续接受主动脉移植物感染治疗的117例患者。52例患者接受了人工血管原位重建,49例接受了腋股动脉重建,16例接受了其他重建。接受完全(n = 35)或部分(n = 17)移植物切除的原位重建患者纳入主要分析。如前所述,对34例原位重建患者和43例腋股动脉重建患者(非同期组)进行了第二项分析。主要结局指标为早期和晚期手术相关死亡、移植物原发性通畅率和肢体丢失情况。次要结局为手术并发症、患者生存率和移植物再感染率。
接受原位重建治疗的患者中,男性40例,女性12例,平均年龄69岁。43例患者使用了浸有利福平的移植物,39例患者使用了网膜瓣或其他自体组织覆盖。23例患者(44%)发生手术并发症。中位随访3.4年(范围2个月至9.6年)后,有4例早期死亡,无晚期手术相关死亡。5年时原发性通畅率和肢体挽救率分别为89%和100%。6例患者(11.5%)发生移植物再感染,且与手术相关死亡无关。在比较分析中,原位重建治疗患者的手术相关死亡率与腋股动脉重建治疗患者无差异(9%对23%;P = 0.11)。5年时原位重建和腋股动脉重建的原发性通畅率有显著改善(89%对48%;P = 0.01)。5年时原位重建的肢体挽救率为100%,腋股动脉重建为89%(P = 0.06)。两组移植物再感染发生率相似:原位重建为11%,腋股动脉重建为17%(P = 0.28)。原位重建后12例患者(30%)和腋股动脉重建后26例患者(60%)发生主要并发症或手术相关死亡(P < 0.04)。
原位重建是治疗特定主动脉移植物感染患者的一种安全有效的替代方法。11.5%的患者发生移植物再感染。移植物通畅率和肢体挽救率极佳。